Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Operating Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Operating Expenses for 8 consecutive years, with $98.7 million as the latest value for Q1 2026.

  • Quarterly Operating Expenses rose 21.43% to $98.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $387.1 million through Feb 2026, up 34.83% year-over-year, with the annual reading at $369.6 million for FY2025, 38.15% up from the prior year.
  • Operating Expenses for Q1 2026 was $98.7 million at Nurix Therapeutics, up from $96.7 million in the prior quarter.
  • The five-year high for Operating Expenses was $99.3 million in Q3 2025, with the low at $52.4 million in Q1 2022.
  • Average Operating Expenses over 5 years is $70.0 million, with a median of $60.6 million recorded in 2024.
  • The sharpest move saw Operating Expenses soared 77.31% in 2022, then increased 0.51% in 2023.
  • Over 5 years, Operating Expenses stood at $55.5 million in 2022, then grew by 9.05% to $60.5 million in 2023, then rose by 28.84% to $77.9 million in 2024, then increased by 24.03% to $96.7 million in 2025, then grew by 2.15% to $98.7 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $98.7 million, $96.7 million, and $99.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.